ACR meeting to highlight digital mammography
With Food and Drug Administration approval for a full-field digital mammography system finally arriving this year, the new imaging technique will be a hot topic at the American College of Radiology’s 29th conference on breast cancer in San
With Food and Drug Administration approval for a full-field digital mammography system finally arriving this year, the new imaging technique will be a hot topic at the American College of Radiologys 29th conference on breast cancer in San Francisco.
The meeting will be held April 8 through 11 at the San Francisco Hilton.
In addition to digital mammography, panels at the convention will cover malpractice, breast cancer diagnosis, breast pathology, and management dilemmas.
The FDA gave premarket approval for GE Medical Systems full-field digital mammography unit, the Senographe 2000D, in February. GE will display the system at the conferences exhibit hall, said Amy Hobert, GEs mammography marketing manager.
We wont be doing a lecture (using the system) but we will have a hands-on demonstration, and well have written information about the machine, Hobert said.
GE has sold 15 Senographe 2000Ds in the U.S. and 25 in Europe, according to Hobert.
GE has FDA approval to market the $500,000 unit for hard-copy use only. This means system users will be limited initially to reading digitally processed hard copies. Marketing the unit as a hard-copy device will give clinicians time to become familiar with the new technology before its marketed in soft-copy, said Charlie Young, GE spokesperson (SCAN 2/16/00).
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
